Pulmonx Corp LUNG
We take great care to ensure that the data presented and summarized in this overview for Pulmonx Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LUNG
View all-
Primecap Management CO Pasadena, CA5.16MShares$8.21 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.56MShares$5.66 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$4.24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$3.65 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.89MShares$3.01 Million0.11% of portfolio
-
Jefferies Group LLC New York, NY1.2MShares$1.91 Million0.2% of portfolio
-
Bnp Paribas Asset Management Holding S.A.1.17MShares$1.86 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.17MShares$1.85 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.13MShares$1.79 Million0.0% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY931KShares$1.48 Million0.02% of portfolio
Latest Institutional Activity in LUNG
Top Purchases
Top Sells
About LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Insider Transactions at LUNG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2025
|
Richard Ferrari |
SELL
Open market or private sale
|
Direct |
8,000
-8.42%
|
$24,000
$3.16 P/Share
|
|
Jun 05
2025
|
Daniel P Florin |
BUY
Open market or private purchase
|
Direct |
23,321
+16.59%
|
$69,963
$3.06 P/Share
|
|
Jun 02
2025
|
Thomas William Burns |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+33.61%
|
-
|
|
Jun 02
2025
|
Tiffany Sullivan |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+33.07%
|
-
|
|
Jun 02
2025
|
Mehul Joshi Chief Financial Officer & PAO |
SELL
Open market or private sale
|
Direct |
8,061
-1.83%
|
$24,183
$3.13 P/Share
|
|
Jun 02
2025
|
Richard Ferrari |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+28.11%
|
-
|
|
Jun 02
2025
|
Steven S. Williamson PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
9,923
-1.33%
|
$29,769
$3.13 P/Share
|
|
Jun 02
2025
|
Georgia Melenikiotou |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+27.15%
|
-
|
|
Jun 02
2025
|
Glendon E. French Iii |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+3.48%
|
-
|
|
Jun 02
2025
|
Daniel P Florin |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+28.35%
|
-
|
|
Jun 02
2025
|
David Aaron Lehman GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
10,457
-0.75%
|
$31,371
$3.13 P/Share
|
|
Jun 02
2025
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,947
-0.36%
|
$20,841
$3.13 P/Share
|
|
Jun 02
2025
|
Dana G Mead Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
37,153
+27.15%
|
-
|
|
Mar 20
2025
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
20,000
-1.98%
|
$140,000
$7.85 P/Share
|
|
Mar 03
2025
|
Mehul Joshi Chief Financial Officer & PAO |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+32.73%
|
-
|
|
Mar 03
2025
|
Mehul Joshi Chief Financial Officer & PAO |
SELL
Open market or private sale
|
Direct |
14,384
-11.21%
|
$100,688
$7.12 P/Share
|
|
Mar 03
2025
|
David Aaron Lehman GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+27.59%
|
-
|
|
Mar 03
2025
|
David Aaron Lehman GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
22,355
-2.34%
|
$156,485
$7.31 P/Share
|
|
Mar 03
2025
|
Steven S. Williamson PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
181,696
+32.58%
|
-
|
|
Mar 03
2025
|
Steven S. Williamson PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
27,689
-12.47%
|
$193,823
$7.14 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 766K shares |
|---|---|
| Open market or private purchase | 37.6K shares |
| Open market or private sale | 274K shares |
|---|